{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029249","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.289435+00:00","generated_at":"2026-06-05T00:08:17.317255+00:00","sec_items":["1.01","2.02","3.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexeo Therapeutics reports FY2023 net loss $66.4M, raises $95M in private placement, extends runway into 2027","bullets":["Net loss $66.4M for 2023 ($12.40/share) vs $59.3M in 2022; cash $121.5M at year-end.","$95M private placement at $15.13/share; co-led by Braidwell and Adage Capital; expected close March 13.","LX2006 Cohort 2 shows positive frataxin increase; interim data from SUNRISE-FA expected mid-2024.","LX2020 granted FDA Fast Track and Orphan Drug Designation; first patient dosing expected in 1H 2024.","Cash runway extended to fund operations into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029249","json":"https://secwatch.observer/filing/0000950170-24-029249.json","markdown":"https://secwatch.observer/filing/0000950170-24-029249.md","text":"https://secwatch.observer/filing/0000950170-24-029249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/0000950170-24-029249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/lxeo-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:08:17.317255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a531ef9b446452580c9123b81e8e9a2732f5097d","claim":"Lexeo Therapeutics, Inc. reported financial results for fourth quarter and full year 2023.","evidence_excerpt":"On March 11, 2024, the Company issued a press release announcing business highlights and its financial results for the three and twelve-months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/0000950170-24-029249-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f10b0e1cbe63eb954a635f5e07bee0b7a55aee96","claim":"Lexeo Therapeutics, Inc. entered into Common Stock Purchase Agreement with certain qualified institutional buyers and institutional accredited investors valued at approximately $95 million (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Lexeo Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain qualified institutional buyers and institutional accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/0000950170-24-029249-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain qualified institutional buyers and institutional accredited investors"},{"label":"Value","value":"approximately $95 million"},{"label":"Effective","value":"2024-03-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}